Literature DB >> 17152006

Frequent and asymptomatic oropharyngeal shedding of human herpesvirus 8 among immunocompetent men.

Corey Casper1, Elizabeth Krantz, Stacy Selke, Steven R Kuntz, Jie Wang, Meei-Li Huang, John S Pauk, Lawrence Corey, Anna Wald.   

Abstract

BACKGROUND: Little is known about the clinical and virologic manifestations of human herpesvirus (HHV)-8 infection in immunocompetent persons in the absence of malignancy.
METHODS: A total of 46 human immunodeficiency virus-negative, HHV-8-seropositive men collected saliva daily, and 25 recorded 15 common symptoms daily (gastrointestinal, constitutional, and oropharyngeal) and absences from work or school. Quantitative polymerase chain reaction measured HHV-8 DNA in saliva.
RESULTS: Some 44 (96%) of 46 men reported having sex with men (MSM). Of the 44 MSM, 27 (61%) had HHV-8 detected in saliva on > or = 1 day; heterosexual men also shed HHV-8. In analyses restricted to MSM, HHV-8 DNA was detected on 636 (22%) of 2897 days. Among MSM with HHV-8 detected in saliva, the median rate was 20% (range, 1%-100%), with 30% shedding on > 50% of days, and the median quantity was 4.5 log10 copies/mL (range, 2.0-7.3 log10 copies/mL). The quantity of HHV-8 shed was lower in nonwhites (P<.001) and younger participants (P=.03). The frequency of HHV-8 detection and quantity were correlated (r=0.62; P<.001). Symptoms were reported on 10 (9%) of 114 days when HHV-8 was present, compared with 78 (9%) of 830 days without (odds ratio, 0.93 [95% confidence interval, 0.30-2.88]; P=.9).
CONCLUSIONS: HHV-8 is detected frequently and intermittently in the saliva of chronically infected immunocompetent MSM, but this infection is asymptomatic.

Entities:  

Mesh:

Year:  2006        PMID: 17152006      PMCID: PMC2128060          DOI: 10.1086/509621

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  45 in total

Review 1.  Kaposi's sarcoma.

Authors:  K Antman; Y Chang
Journal:  N Engl J Med       Date:  2000-04-06       Impact factor: 91.245

Review 2.  Epidemiology of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8.

Authors:  T F Schulz
Journal:  Adv Cancer Res       Date:  1999       Impact factor: 6.242

3.  Sensitive method for detection of human herpesviruses 6 and 7 in saliva collected in field studies.

Authors:  D M Zerr; M L Huang; L Corey; M Erickson; H L Parker; L M Frenkel
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

4.  Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.

Authors:  A Wald; J Zeh; S Selke; T Warren; A J Ryncarz; R Ashley; J N Krieger; L Corey
Journal:  N Engl J Med       Date:  2000-03-23       Impact factor: 91.245

5.  Mucosal shedding of human herpesvirus 8 in men.

Authors:  J Pauk; M L Huang; S J Brodie; A Wald; D M Koelle; T Schacker; C Celum; S Selke; L Corey
Journal:  N Engl J Med       Date:  2000-11-09       Impact factor: 91.245

6.  Bone marrow failure associated with human herpesvirus 8 infection after transplantation.

Authors:  M Luppi; P Barozzi; T F Schulz; G Setti; K Staskus; R Trovato; F Narni; A Donelli; A Maiorana; R Marasca; S Sandrini; G Torelli
Journal:  N Engl J Med       Date:  2000-11-09       Impact factor: 91.245

7.  Human herpesvirus 8 seroprevalence and evaluation of nonsexual transmission routes by detection of DNA in clinical specimens from human immunodeficiency virus-seronegative patients from central and southern Italy, with and without Kaposi's sarcoma.

Authors:  P Cattani; M Capuano; F Cerimele; I L La Parola; R Santangelo; C Masini; D Cerimele; G Fadda
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

8.  Human herpesvirus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases.

Authors:  G Rezza; M Andreoni; M Dorrucci; P Pezzotti; P Monini; R Zerboni; B Salassa; V Colangeli; L Sarmati; E Nicastri; M Barbanera; R Pristerà; F Aiuti; L Ortona; B Ensoli
Journal:  J Natl Cancer Inst       Date:  1999-09-01       Impact factor: 13.506

9.  Shedding of cytomegalovirus and herpesviruses 6, 7, and 8 in saliva of human immunodeficiency virus type 1-infected patients and healthy controls.

Authors:  E Lucht; M Brytting; L Bjerregaard; I Julander; A Linde
Journal:  Clin Infect Dis       Date:  1998-07       Impact factor: 9.079

10.  Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples.

Authors:  A J Ryncarz; J Goddard; A Wald; M L Huang; B Roizman; L Corey
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

View more
  45 in total

1.  Herpes viruses and HIV-1 drug resistance mutations influence the virologic and immunologic milieu of the male genital tract.

Authors:  Sara Gianella; Sheldon R Morris; Christy Anderson; Celsa A Spina; Milenka V Vargas; Jason A Young; Douglas D Richman; Susan J Little; Davey M Smith
Journal:  AIDS       Date:  2013-01-02       Impact factor: 4.177

2.  Prospective Characterization of the Risk Factors for Transmission and Symptoms of Primary Human Herpesvirus Infections Among Ugandan Infants.

Authors:  Soren Gantt; Jackson Orem; Elizabeth M Krantz; Rhoda Ashley Morrow; Stacy Selke; Meei-Li Huang; Joshua T Schiffer; Keith R Jerome; Annet Nakaganda; Anna Wald; Corey Casper; Lawrence Corey
Journal:  J Infect Dis       Date:  2016-02-24       Impact factor: 5.226

Review 3.  HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease.

Authors:  Ryan J Sullivan; Liron Pantanowitz; Corey Casper; Justin Stebbing; Bruce J Dezube
Journal:  Clin Infect Dis       Date:  2008-11-01       Impact factor: 9.079

4.  Early childhood infection of Kaposi's sarcoma-associated herpesvirus in Zambian households: a molecular analysis.

Authors:  Landon N Olp; Danielle M Shea; Maxine K White; Clement Gondwe; Chipepo Kankasa; Charles Wood
Journal:  Int J Cancer       Date:  2012-08-20       Impact factor: 7.396

5.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

Review 6.  KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine.

Authors:  Don Ganem
Journal:  J Clin Invest       Date:  2010-04-01       Impact factor: 14.808

Review 7.  HIV-Associated Cancers and Related Diseases.

Authors:  Robert Yarchoan; Thomas S Uldrick
Journal:  N Engl J Med       Date:  2018-03-15       Impact factor: 91.245

8.  Oral shedding of herpesviruses in HIV-infected patients with varying degrees of immune status.

Authors:  Dirk P Dittmer; Kristen Tamburro; Huichao Chen; Anthony Lee; Marcia K Sanders; Tischan A Wade; Sonia Napravnik; Jennifer Webster-Cyriaque; Mahmoud Ghannoum; Caroline H Shiboski; Judith A Aberg
Journal:  AIDS       Date:  2017-09-24       Impact factor: 4.177

9.  Consistent viral DNA quantification after prolonged storage at ambient temperature.

Authors:  Benjamin Zaniello; Meei-Li Huang; Anqi Cheng; Stacy Selke; Anna Wald; Keith R Jerome; Amalia S Magaret
Journal:  J Virol Methods       Date:  2015-11-22       Impact factor: 2.014

10.  Impact of HIV infection and Kaposi sarcoma on human herpesvirus-8 mucosal replication and dissemination in Uganda.

Authors:  Christine Johnston; Jackson Orem; Fred Okuku; Mary Kalinaki; Misty Saracino; Edward Katongole-Mbidde; Merle Sande; Allan Ronald; Keith McAdam; Meei-Li Huang; Linda Drolette; Stacy Selke; Anna Wald; Lawrence Corey; Corey Casper
Journal:  PLoS One       Date:  2009-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.